iRadimed
IRMD
213 hedge funds and large institutions have $750M invested in iRadimed in 2026 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 98 increasing their positions, 61 reducing their positions, and 30 closing their positions.
61% more repeat investments, than reductions
Existing positions increased: 98 | Existing positions reduced: 61
24% more capital inflows, than outflows
Capital inflows: $100M | Capital outflows: $80.5M
1.73% more ownership
Funds ownership: 59.69% → 61.42% (+1.7%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
7% less funds holding
Funds holding: 228 → 213 (-15)
18% less call options, than puts
Call options by funds: $1.29M | Put options by funds: $1.58M
40% less first-time investments, than exits
New positions opened: 18 | Existing positions closed: 30
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$11.7M |
| 2 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$10.8M |
| 3 |
First Trust Advisors
Wheaton,
Illinois
|
+$7.47M |
| 4 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$6.72M |
| 5 |
Granahan Investment Management
Waltham,
Massachusetts
|
+$6.38M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NTCM
Nine Ten Capital Management
Chicago,
Illinois
|
-$7.1M |
| 2 |
SG Americas Securities
New York
|
-$5.84M |
| 3 |
Jane Street
New York
|
-$5M |
| 4 |
EAM Investors
Solana Beach,
California
|
-$4.81M |
| 5 |
Renaissance Technologies
New York
|
-$4.22M |
IRMD Hedge Fund Activity: Q2 2026 in Review
213 of the 8,358 institutional investors tracked by Wall St. Rank reported a position in iRadimed (IRMD) for Q2 2026, worth a combined $750M — up 2.2% from $734M a quarter earlier.
Sellers outnumbered buyers: 30 funds closed out of IRMD and 18 opened new positions — a net loss of 12 holders — while 61 trimmed existing stakes and 98 added.
The largest buyer was Arrowstreet Capital, adding an estimated $11.7M. The largest seller was Nine Ten Capital Management, cutting an estimated $7.1M.
- 213 institutional investors held iRadimed (IRMD) as of Q2 2026, down from 228 in Q1 2026.
- Funds reported $750M of iRadimed stock for Q2 2026, up 2.2% quarter-over-quarter.
- 18 funds opened new iRadimed positions in Q2 2026 and 30 closed out, a net change of -12 holders.
- The largest iRadimed buyer in Q2 2026 was Arrowstreet Capital, an estimated $11.7M added.
- The largest iRadimed seller in Q2 2026 was Nine Ten Capital Management, an estimated $7.1M sold.
Based on aggregated 13F filings for Q2 2026.